Your SlideShare is downloading. ×
 PharmaPoint: Meningococcal Vaccines - Brazil Drug Market 2022:New Industry Analysis Report
 PharmaPoint: Meningococcal Vaccines - Brazil Drug Market 2022:New Industry Analysis Report
 PharmaPoint: Meningococcal Vaccines - Brazil Drug Market 2022:New Industry Analysis Report
 PharmaPoint: Meningococcal Vaccines - Brazil Drug Market 2022:New Industry Analysis Report
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

PharmaPoint: Meningococcal Vaccines - Brazil Drug Market 2022:New Industry Analysis Report

106

Published on

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment …

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
106
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022 GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Brazil Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. GlobalData predicts that market share for private vaccine manufacturers to virtually disappear over the course of the forecast, with Brazil unleashing domestically-produced MenC conjugate vaccines that are more cost-effective for the government-funded healthcare system. These vaccines, which include a MenC conjugate vaccine and a heptavalent pediatric vaccine (DTP-Hib-HepB-IPV-MenC) are being developed and produced by government-sponsored institutions such as Bio-Manguinhos, Instituto Butantan, Fiocruz, and FUNED. Once they become widely available, these vaccines will quickly steal market share from private manufacturers because of their cost-effectiveness advantage. Scope Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in Brazil from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting Brazil Meningococcal Vaccines market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in Brazil table Of Contents 1 Table Of Contents 4 1.1 List Of Tables 7 1.2 List Of Figures 9 PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022
  • 2. 2 Introduction 10 2.1 Catalyst 10 2.2 Related Reports 11 2.3 Upcoming Related Reports 13 3 Disease Overview 14 3.1 Etiology And Pathophysiology 15 3.1.1 Etiology 15 3.1.2 Pathophysiology 17 3.2 Symptoms 19 3.3 Prognosis 20 4 Disease Management 21 4.1 Meningococcal Immunization Policy 22 4.2 Brazil 24 4.2.1 Meningococcal Immunization Recommendations And Policies 24 4.2.2 Clinical Practice 26 5 Competitive Assessment 28 5.1 Overview 28 5.2 Strategic Competitor Assessment 28 5.3 Product Profiles Major Brands 30 5.3.1 Meningitec 30 5.3.2 Menjugate 33 5.3.3 Neisvac-c 36 6 Opportunity And Unmet Need 39 6.1 Overview 39 6.2 Unmet Needs 40 6.2.1 Unmet Need: Protection Against Serogroup B Disease 40 6.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 41 6.2.3 Unmet Need: More Cost-effective Vaccines 42 6.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 43 6.2.5 Unmet Need: Immunogenic Infant Vaccines 45 6.2.6 Unmet Need: Improved Vaccination Coverage Rates 46 6.2.7 Unmet Need: Increased Patient Awareness And Education 47 6.3 Unmet Needs Gap Analysis 48 6.4 Opportunities 49 6.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 49 PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022
  • 3. 6.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 50 6.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging Markets 51 7 Pipeline Assessment 52 7.1 Overview 52 7.2 Promising Vaccines In Clinical Development 53 7.2.1 Promising Vaccines In Early Clinical Development 56 7.2.2 Meninge Acyw Conj. 57 7.2.3 Menabcwy 61 7.2.4 Menc Conjugate 64 7.2.5 Heptavalent Dtp-hib-hepb-ipv-menc 67 8 Market Outlook 70 8.1 Brazil 70 8.1.1 Forecast 70 8.1.2 Key Events 73 8.1.3 Drivers And Barriers 74 9 Appendix 76 9.1 Bibliography 76 9.2 Abbreviations 87 9.3 Methodology 90 9.4 Forecasting Methodology 90 9.4.1 Vaccine Coverage 91 9.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 91 9.4.3 Vaccines Included 92 9.4.4 General Pricing Assumptions 93 9.4.5 Individual Vaccine Assumptions 94 9.5 Physicians And Specialists Included In This Study 97 9.6 About The Authors 101 9.6.1 Authors 101 9.6.2 Reviewers 101 9.6.3 Global Head Of Healthcare 103 9.7 About Globaldata 104 9.8 Disclaimer 104 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022
  • 4. industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

×